Replies to post #529684 on NorthWest Biotherapeutics Inc (NWBO)

[Hopeforthefuture3]

Not much revenue from the specials program - was hoping to see quite a bit more

[VuBru]

So from April - September 2022 they have been paying consultants for help in preparing documents for DCVAX regulatory approval. That is what I wanted to hear.

[StonkMaster]

Our lead product, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. We have completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM ). On May 10, 2022, top line data from the Phase III trial were presented in a scientific conference at the New York Academy of Sciences by one of the investigators in the trial. The presentation was made available publicly on a third-party site.

The Company is now working on preparations for seeking regulatory approval of DCVax-L.